Scarica l'app Stockscreener
68.91
9.92%
6.22
Dopo l'orario di chiusura:
68.44
-0.47
-0.68%
Precedente Chiudi:
$62.69
Aprire:
$65
Volume 24 ore:
21.70M
Relative Volume:
1.67
Capitalizzazione di mercato:
$9.03B
Reddito:
$640.44M
Utile/perdita netta:
$-743.28M
Rapporto P/E:
-6.1043
EPS:
-11.2888
Flusso di cassa netto:
$-206.93M
1 W Prestazione:
+32.04%
1M Prestazione:
+63.60%
6M Prestazione:
+1.22%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$64.00
$71.42
Intervallo di 1 settimana:
$48.71
$71.42
Portata 52W:
$22.89
$91.45
Tempus Ai Inc Stock (TEM) Company Profile
Nome
Tempus Ai Inc
Settore
Industria
Telefono
800-976-5448
Indirizzo
600 WEST CHICAGO AVENUE, CHICAGO
Confronta TEM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
68.91 | 9.03B | 640.44M | -743.28M | -206.93M | -11.29 |
|
VEEV
Veeva Systems Inc
|
241.20 | 38.62B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
60.43 | 11.14B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
96.99 | 7.91B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
39.11 | 7.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Iniziato | BTIG Research | Buy |
| 2025-02-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | Ripresa | TD Cowen | Buy |
| 2024-12-13 | Iniziato | Wolfe Research | Outperform |
| 2024-12-09 | Iniziato | Guggenheim | Buy |
| 2024-11-11 | Downgrade | Stifel | Buy → Hold |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-08-12 | Iniziato | Piper Sandler | Neutral |
| 2024-07-09 | Iniziato | BofA Securities | Buy |
| 2024-07-09 | Iniziato | JP Morgan | Overweight |
| 2024-07-09 | Iniziato | Longbow | Buy |
| 2024-07-09 | Iniziato | Loop Capital | Buy |
| 2024-07-09 | Iniziato | Morgan Stanley | Overweight |
| 2024-07-09 | Iniziato | Needham | Buy |
| 2024-07-09 | Iniziato | Stifel | Buy |
| 2024-07-09 | Iniziato | TD Cowen | Buy |
| 2024-07-09 | Iniziato | William Blair | Outperform |
Mostra tutto
Tempus Ai Inc Borsa (TEM) Ultime notizie
Is Tempus AI, Inc. (TEM) the Best Performing Healthcare Stock to Buy Now? - Yahoo Finance
Tradr Launches First Leveraged ETF on Tempus AI - PR Newswire
Biovica collaborates with Tempus to expand the commercial reach of DiviTum® TKa - TradingView
Tempus AI Reports Strong Growth and Strategic Partnerships in Earnings Call - MSN
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Jim Cramer Says Stay Away from This Nancy Pelosi Stock - MSN
These AI Stocks Posted Robust Results: Time to Buy? - The Globe and Mail
The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Tempus AI Stock: Time to Double Down or Cut and Run? - MSN
Morgan Stanley raises Tempus AI price target to $65 from $60 - Investing.com Australia
Tempus AI COO Ryan Fukushima Sells 20,000 Shares - TradingView
Tempus AI, Inc. Class A (TEM) Gets a Hold from Piper Sandler - The Globe and Mail
Why Tempus AI, Inc. (TEM) Skyrocketed On Wednesday - Insider Monkey
Why These 10 Stocks Soared Today - Insider Monkey
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals - Benzinga
Tempus AI price target raised to $65 from $60 at BTIG - TipRanks
Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight - GlobeNewswire Inc.
U.S. STOCKS ON THE MOVE-Bio-Techne, Johnson Controls, Tempus AI - TradingView
What’s Next For Tempus AI Stock? - Forbes
Tempus AI, Inc. (TEM): Among Most Popular Stocks on Robinhood in 2025 - Insider Monkey
Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressures - Benzinga
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga
Tempus AI raises revenue guidance to $1.25B for 2025, supported by new $200M AstraZeneca deal - MSN
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Tempus: Q1 Earnings Snapshot - MySA
Earnings call transcript: Tempus AI Q1 2025: Revenue Surges, Stock Dips - Investing.com India
Tempus AI Inc Reports Q1 2025 Revenue of $255.7 Million and Net Loss of $68 Million - GuruFocus
On heels of big data deals, Tempus AI touts robust revenue - Crain's Chicago Business
Tempus AI beats Q1 expectations, raises 2025 outlook; shares dip 2.3% - Investing.com Nigeria
Tempus AI Q1 2025 slides: revenue surges 75%, approaching EBITDA profitability - Investing.com India
Tempus AI Q1 Non-GAAP Loss Narrows; Revenue Rises; Slightly Ups Full Year Guidance - marketscreener.com
Tempus AI reports Q1 adjusted EPS (24c), consensus (27c) - TipRanks
Earnings Flash (TEM) Tempus AI Reports Q1 Revenue $255.7M, vs. FactSet Est of $248.1M - marketscreener.com
Tempus Reports First Quarter 2025 Results - Bluefield Daily Telegraph
Tempus AI Stock Dips as Earnings on Deck (NASDAQ: TEM) – What To Expect - AskTraders.com
Tempus selects TIME Network for Phase I clinical trials - MSN
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect - AOL.com
tempus AI Inc Class A call volume above normal and directionally bullish - TipRanks
Tempus AI (Nasdaq: TEM) Earnings: Live Coverage And What to Expect - 24/7 Wall St.
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. - AOL.com
Jim Cramer Warns on Tempus AI (TEM): “Diagnostics With no Dough? I’m Out” - Insider Monkey
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - The Globe and Mail
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry - Business Wire
Tempus Ai Inc Azioni (TEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tempus Ai Inc Azioni (TEM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fukushima Ryan | Chief Operating Officer |
May 06 '25 |
Sale |
52.36 |
20,000 |
1,047,239 |
884,460 |
| Epstein David R | Director |
May 01 '25 |
Sale |
53.50 |
370 |
19,795 |
25,914 |
| Gottlieb Scott | Director |
Apr 01 '25 |
Sale |
47.21 |
27,837 |
1,314,154 |
32,839 |
| Doudna Jennifer A | Director |
Apr 01 '25 |
Sale |
48.12 |
625 |
30,075 |
25,740 |
| Fukushima Ryan | Chief Operating Officer |
Apr 01 '25 |
Sale |
47.20 |
20,000 |
944,085 |
904,460 |
| Frederick Wayne A.I. | Director |
Mar 31 '25 |
Sale |
45.54 |
3,000 |
136,620 |
26,514 |
0.34%
2.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):